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We examined the eﬀect of intact human mast cells (HMC-1 5C6) and their selected mediators on interleukin-6 (IL-6) production
and bone morphogenetic protein-2 (BMP-2) expression in human coronary artery endothelial cells (HCAEC) in the presence and
absenceoflipopolysaccharide(LPS).ScanningelectronmicroscopyshowedthatHMC-15C6cellsadheretoHCAECincocultures.
AdditionofHMC-15C6cellsmarkedlyenhancedtheIL-6productionbyquiescentandLPS-activatedHCAECevenatthemaximal
concentration of LPS. Furthermore, mast cell-derived histamine and proteases accounted for the direct and synergistic eﬀect of
mast cells on IL-6 production that was completely blocked by the combination of histamine receptor-1 antagonist and protease
inhibitors. Another novel ﬁnding is that histamine was able to induce BMP-2 expression in HCAEC. Collectively, our results
suggest that endotoxin and mast cell products synergistically amplify vascular inﬂammation and that histamine participates in the
early events of vascular calciﬁcation.
1.Introduction
Mast cells are normal constituents of the vessel wall and
are primarily located in the connective tissue matrices.
Increasing evidence suggests an important role for mast cells
in vascular inﬂammation and atherosclerosis [1–4], ﬁbrosis
[5], osteoporosis [6], and host defense [7]. The adventitia
of coronary arteries of patients with atherosclerotic plaques
contains increased number of mast cells [1–3, 8–10]. An
increase in the number of tissue mast cells is also found
to be associated with thrombus formation [3]. Mast cell
granules have been identiﬁed within endothelial cells in
vivo [11] and are known to cause proliferation of human
microvascular endothelial cells [12]. Furthermore, mast
cell granule remnants can bind to low-density lipoproteins
(LDL) and enhance their uptake by macrophages leading to
the development of foam cells [13, 14]. We have previously
shown that granules isolated from rat peritoneal mast
cells interact with human endothelial cells in culture and
enhance lipopolysaccharide- (LPS-) induced production of
interleukin-6(IL-6)andIL-8[15–17].Theseﬁndingssuggest
that mast cells play an important role in endothelial cell acti-
vation and vascular inﬂammation. However, the interaction
of human mast cells with human endothelial cells and its
impact on inﬂammatory responses has not been evaluated.
Vascular endothelium regulates many aspects of the in-
ﬂammatory response in addition to its well-recognized func-
tionasaprotectivebarrierbetweenbloodandtissues.Activa-
tion of endothelial cells and resultant enhancement in the
production of proinﬂammatory cytokines, prostanoids, and
the expression of adhesion molecules are critical factors for
the immune response and host defense as well as for the pro-
gressionofinﬂammatorydiseases.Thecascadeofendothelial
activation can be initiated by both endogenous agonists2 Mediators of Inﬂammation
such as inﬂammatory cytokines, lipid mediators, histamine,
and proteases, and by exogenous agents including microbial
agents. We have shown that the cell wall components of
both gram-positive and gram-negative bacteria can induce
inﬂammatory responses in human endothelial cells [15–
18] suggesting an important role for infectious agents in
initiating vascular inﬂammation.
Mast cells synthesize and secrete many vasoactive sub-
stances and inﬂammatory mediators including histamine,
proteases (tryptase, chymase, and carboxypeptidase A)
prostaglandin D2, leukotrienes, heparin, and cytokines
[19–23]. Histamine and tryptase are two major secretory
products of mast cells. The involvement of histamine in
vascular disease is suggested by its elevated levels in the
coronary circulation of patients with variant angina [24]
and an increased expression of histamine H1receptor (H1R)
in atherosclerotic lesions [25]. Previous reports from our
laboratory show that histamine induces the expression of
cyclooxygenase-2 and IL-6 mRNA and the production of
PGI2,P G E 2, and IL-6 [18, 26, 27]. A number of reports
have also documented the role of mast cells in the formation
of foam cells [13, 14] and calciﬁcation of plaques [9, 10].
Bone morphogenetic protein-2 (BMP-2) is a key molecule
in the calciﬁcation cascade and its expression in endothelial
cells is induced by TNF-α or by mechanical stimuli [28, 29].
Although mast cells are involved in atherosclerotic plaque
development[9,10],directeﬀectofmastcellcomponentson
the expression of BMP-2 has not been explored. Therefore,
the objective of the present study was to evaluate the eﬀect of
intact human mast cells and their products on the regulation
of inﬂammatory and calciﬁcation responses in na¨ ıve and
LPS-activated HCAEC.
2.MaterialsandMethods
2.1. Cells. Human coronary artery endothelial cells and
endothelial cell growth medium (EGM-2MV) were obtained
from Cambrex (San Diego, CA). Human mast cell line, sub-
clone HMC-1 5C6 (derived from HMC-1 cells) was kindly
provided by Dr. Michel Arock (Ecole Normale Sup´ erieure de
Cachan, Cachan, France).
2.2. Culture of Endothelial Cells. HCAEC were grown
in EGM-2MV containing 1μg/mL hydrocortisone acetate,
50ng/mL gentamycin, 50μg/mL amphotericin B, and the
recommended concentrations of human epidermal growth
factor, vascular endothelial growth factor, human ﬁbroblast
growth factor, recombinant insulin-like growth factor-1,
ascorbic acid, and 5% fetal bovine serum as described
previously [15, 16]. At conﬂuence, cells were detached
from the culture ﬂasks using trypsin-EDTA, washed twice,
and resuspended in fresh EGM-2MV. The cells used in all
experiments were between passages three and six.
2.3. Mast Cells. HMC-1 5C6 cells were grown in Iscove’s
Modiﬁed Dulbecco’s medium containing 10% FBS and
50μM of 2-mercaptoethanol at 37◦C and 5% CO2. When
applicable, mast cells were pretreated overnight with pro-
tease inhibitor cocktail (Sigma Chemical Co., St. Louis,
Mo) containing 4-(2-aminoethyl)benzenesulfonyl ﬂuoride
hydrochloride 1mM, bestatin 40μM, E-64 14μM, leupeptin
20μM, pepstatin 15μM, and aprotinin 0.8μM. Protease
inhibitor-treatedmastcellswereincubatedwithHCAECand
washed twice with EGM-2MV. Mast cells treated with EGM-
2MV containing 1% DMSO were used as controls since
DMSO was used as the vehicle to resuspend the protease
inhibitor cocktail.
2.4. Determination of IL-6 Production. HCAEC were seeded
onto96-wellcellcultureplate(1×104cells/well)andallowed
to adhere for 16 to 18h. Following adherence, endothelial
cell monolayers were incubated with mast cells or lysates
derived from equivalent counts of mast cells in the presence
or absence of LPS in a ﬁnal volume of 0.2mL at 37◦Cu n d e r
5% humidiﬁed CO2. After the indicated incubation period,
culture supernatants were harvested, appropriately diluted,
and assayed for IL-6 levels by ELISA [16–18].
2.5. Real-Time PCR (qRT-PCR) Analysis of the Expression of
BMP-2. HCAEC monolayers were incubated with medium,
histamine, cetirizine, histamine + cetirizine, or with LPS
(10 and 100ng/mL) for 2h. Following incubation, super-
natant was removed and total RNA was isolated using
RNeasy Mini Kit (Qiagen, Valencia, CA), according to
the manufacturer’s protocol. Total RNA (1μg) was reverse
transcribed into ﬁrst-strand cDNA using High-Capacity
cDNA Achieve Kit (Applied Biosystems, Foster City, CA)
following the manufacturer’s procedure. The primers used
for SYBR Green real-time RT-PCR were designed using the
Primer Express Software v3.0 (Applied Biosystems, Foster
City, CA). The sequences of primers used for real-time
PCR analyses of various genes are, human BMP-2: forward-
TGCTAGTAACTTTTGGCCATGATG; reverse- GCGTTTC-
CGCTGTTT GTGTT, human β Actin: forward- CCAGCT-
CACCATGGATGATG; reverse- ATGCCGGAGCCGTTGTC.
2.6. Western Blot Analysis of BMP-2. HCAEC monolayers
were incubated with medium, histamine, LPS, or histamine
+ LPS for 2 or 24h. After the incubation, the supernatant
was removed and the cells were sonicated in the lysis
buﬀercontaining1%TritonX100,protease,andphosphatase
inhibitors,andtheywerecentrifuged.Analiquotofthelysate
was transferred to sample wells in 10% Mini-PROTEAN
precast gels (BioRad, Hercules, CA, USA). SDS-PAGE was
carried out in Tris-glycine buﬀer at 60volts for 120min.
Separated proteins were transferred to PVDF membranes
by electroblotting at 90volts for 60min. Fat-free milk
powder (5%) was used as the blocking agent. Rabbit-anti-
human BMP-2 polyclonal antibody (1:500 dilution) was
usedastheprimaryantibody(ab-14933,Abcam,Cambridge,
MA, USA) and HRP-conjugated goat-anti-rabbit antibody
(1:3,000 dilution) as the secondary antibody (ab-6721,
Abcam). β-Actin, the loading control, was detected using
anti-β-actin AC-15 (A5441, Sigma, 1:10,000 dilution) and
HRP-conjugated goat-anti-mouse IgG antibody (170–5047,Mediators of Inﬂammation 3
BioRad, 1:5,000 dilution) as the primary and secondary
antibodies, respectively.
2.7.ElectronMicroscopicAnalysisofMastCell-EndothelialCell
Interaction. Conﬂuent HCAEC were cultured for 24h in the
presence or absence of HMC-1 5C6 cells at a mast cell-
endothelial cell ratio of 1:2. After 24h, cells were washed
twice with fresh phosphate buﬀered saline. Washed cells
were ﬁxed in 2% glutaraldehyde and processed for scanning
electron microscopy. For transmission electron microscopy,
HMC-1 5C6 cells were sedimented by centrifugation. The
pellet was washed and ﬁxed in 2% glutaraldehyde and pro-
cessed at the University of Kansas Medical Center Electron
Microscopy Core Facility.
2.8. Statistical Analysis. Student’s unpaired t-test or two-way
ANOVA were adopted for statistical analyses as applicable.
Results are represented as mean ± SEM and P<0.05 is
considered signiﬁcant.
3. Results
In order to examine the eﬀect of human mast cells, we
compared the direct and synergistic eﬀects of HMC-1 5C6
on IL-6 production by HCAEC.
3.1. Eﬀect of HMC-1 5C6 on IL-6 Production by HCAEC
Stimulated with LPS. The eﬀects of HMC-1 5C6 on IL-6
production by unactivated or LPS-treated HCAEC are pre-
sented in Figure 1. Unactivated HCAEC produced relatively
l o wl e v e l so fI L - 6i na2 4hc u l t u r e .H o w e v e r ,L P Ss t i m u l a t e d
the production of IL-6 by HCAEC in a dose-dependent
manner which attained a plateau at 100ng/mL LPS. Presence
of HMC-1 5C6 in the coculture, at an endothelial cell:
mast cell ratio of 1:1 resulted in a marked potentiation
of LPS-induced IL-6 production at all concentrations of
LPS tested. It is of interest that mast cells alone induced a
small but signiﬁcant increase in IL-6 production by HCAEC.
The ampliﬁcation of LPS-induced cytokine production by
HMC-1 5C6 was evident at LPS concentrations as low as
0.1ng/mL and at higher doses (100 and 1000ng/mL LPS).
Once again, increased levels of IL-6 cannot be attributed to
the IL-6 production by HMC-1 5C6 because these cells did
not generate detectable amounts of IL-6 in the presence or
absence of LPS (data not shown).
3.2. Eﬀect of Endothelial Cell: Mast Cell Ratios on IL-6
Production. As shown in Figure 2, addition of increasing
counts of HMC-1 5C6 cells to a constant number of
HCAEC resulted in progressive increase in the production
of IL-6 both by unactivated and LPS-stimulated cells. The
potentiating eﬀect of HMC-1 5C6 cells on LPS-induced IL-
6 production by HCAEC was linear with the number of
mast cells present in the culture. The mast cell-mediated
ampliﬁcation of LPS-induced IL-6 production was approx-
imately 300% of the control at the HCAEC: mast cell ratio
1:1.
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Figure 1: Mast cells potentiate LPS- induced IL-6 production
by HCAEC. Endothelial cells (10,000cells/well) were grown for
24h in the presence or absence of HMC-1 5C6 (5000cells/well)
and stimulated with indicated concentrations of LPS. Following
incubation, the cell culture supernatants were analyzed for IL-6
by ELISA. Results presented are mean ± SEM of quadruplicate
determinations of a representative experiment. Similar results were
observed in two additional experiments.
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Figure 2: Mast cells dose-dependently potentiate LPS-induced IL-
6 production by HCAEC. Endothelial cells (10,000cells/well) were
grown for 24h in the presence of increasing number of HMC-1 5C6
cells and were activated with LPS (100ng/mL) for a period of 24h.
Aftertheincubation,culturesupernatantswereanalyzed forIL-6by
ELISA. Results are mean ± SEM of quadruplicate determinations of
a representative experiment. Similar results were observed in two
other experiments.
3.3. Transmission and Scanning Electron Microscopy Studies.
The ultrastructural assessment of HMC-1 5C6 cells demon-
strates the presence of cytoplasmic granules (Figure 3).
The subclone HMC-1 5C6 (Figure 3(a)) exhibited several
electron-dense granules (arrows), indicating maturity of
granulesinthesecells.Thescanningelectronmicroscopyfol-
lowing co-culture of HCAEC and HMC-1 5C6 (Figure 3(b))4 Mediators of Inﬂammation
(a) (b)
Figure 3: Transmission and scanning electron microscopy. The ultrastructural assessment of HMC-1 5C6 cells demonstrates the presence
of cytopslasmic granules; (a) shows HMC-1 5C6 clone exhibited numerous electron-dense granules (arrows) indicating maturity of the
cells (magniﬁcation 14,000X); (b) shows a scanning electron micrograph of HMC-1 5C6 in a typical co-culture experiment demonstrating
endothelial cell-mast cell interaction (magniﬁcation 2600X).
demonstrates the interaction between these two cell types in
a2 4hc o c u l t u r e .
3.4. Eﬀect of Intact Mast Cells and Cell Lysate. Results pre-
sented in Table 1 demonstrate that coincubation of HCAEC
with HMC-1 5C6 cells resulted in endothelial cell activation.
This ﬁnding was consistent with our previous results using
r a tm a s tc e l lg r a n u l e s( M C G )[ 16, 17]. As expected, incuba-
tion with LPS caused signiﬁcant increase in IL-6 production
by endothelial cells. The 5C6 subclone-induced cytokine
production was markedly enhanced (300%) by the presence
of LPS (100ng/mL) indicating synergy between human mast
cells and LPS on endothelial cell activation. In addition,
lysates of HMC-1 5C6 subclone showed synergistic eﬀects
with LPS on endothelial cell IL-6 production. The enhanced
levels of IL-6 were not derived from the mast cell lines
because incubation of HMC-1 5C6 subclone with or without
LPS did not generate IL-6 (data not shown). Furthermore,
the mast cell lysate did not contain detectable amounts of
IL-6 (Table 1).
3.5. Role of Histamine and Proteases on the Synergy between
Mast Cells and LPS. Histamine is a major constituent of
the mast cell. The eﬀect of histamine on endothelial cells is
primarily mediated through H1R [18, 26, 27, 30]. Therefore,
to determine whether histamine derived from HMC-1 5C6
mediates the ampliﬁcation of the eﬀect of LPS on HCAEC,
studies were conducted in the presence of 10μM diphen-
hydramine (H1 receptor antagonist) or 10μM famotidine
(H2 receptor antagonist). As shown in Figure 4(a),1 0 μM
diphenhydramine signiﬁcantly inhibited the HMC-1 5C6-
induced potentiation of LPS eﬀect on IL-6 production.
In contrast, H2 receptor antagonist, famotidine, did not
inhibit the potentiating eﬀect of mast cells on LPS response
(Figure 4(b)). The fact that exogenous histamine (10μM)
w a sa b l et os y n e r g i z et h ee ﬀect of LPS on IL-6 production by
Table 1: HMC-1 5C6 directly and synergistically with LPS enhance
endothelial cell production of IL-6.
Treatment No LPS LPS
Control 25 ±3 546 ±19
5C6 (7,500) 82 ±6 1548 ±68
5C6 (15,000) 170 ±9 2238 ±59
5C6-sonicate (7,500 cell equivalent) 118 ±14 1380 ±45
5C6-sonicate (15,000 cell equivalent) 227 ±13 1842 ±62
Conﬂuent human coronary artery endothelial cells (15,000cells/well) were
incubated with the indicated number of human mast cells or their lysate
after sonication in the presence or absence of LPS (100ng/mL). After 20h
of incubation the culture supernatants were assayed for IL-6. HMC-1 5C6
cultured in the absence of HCAEC did generate IL-6 in the presence or
absence of LPS. Each value presented is the mean ± SEM of quadruplicate
determinations.
HCAEC (Figure 5(a)) further conﬁrms the role of mast cell-
derived histamine (Figure 4(a)). Once again, the histamine-
mediated ampliﬁcation of LPS-activation was abrogated by
the H1R antagonist and not by the H2R antagonist. Neither
diphenhydraminenorfamotidinealonehadanyeﬀectonthe
LPS-induced IL-6 production by endothelial cells (Figures 4
and 5). The concentrations of histamine and the receptor
antagonists used here were selected based on optimum
stimulatory and inhibitory eﬀects, respectively [18, 26, 27].
Serine proteases are present in the mast cells [20–23]
and are known to activate endothelial cells [17, 31]. We
determined the eﬀect of mast cell-derived protease(s) on
the LPS-stimulated production of IL-6 by HCAEC. First,
mast cells (MC) were incubated with a cocktail of protease
inhibitors (PI) for 18h (MC + PI) and washed twice
to remove PI. The mast cell suspension free of PI was
incubated with HCAEC cultures. Figure 4(c) shows that
addition of untreated mast cells potentiated the eﬀect of LPS
asanticipated.Incontrast,mastcellspretreatedwithproteaseMediators of Inﬂammation 5
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Figure 4:CombinationofH1Rantagonistandproteaseinhibitors(PI)abrogatesmastcell-(MC-)mediatedpotentiationofIL-6production
by LPS-stimulated endothelial cells. Endothelial cells (10,000cells/well) were grown for 24h in the presence of mast cells (5000cells/well)
and were activated with LPS (100ng/mL) for a period of 24h. To determine the eﬀect of H1R or H2R antagonists, endothelial cells were
incubatedwith10μMdiphenhydramine(DPH)(a)or10μMfamotidine(FAM)(b)for30minbeforeadditionofHMC-15C6.Todetermine
the contribution of mast cells proteases (c), HMC-1 5C6 were pretreated with protease inhibitor (PI) cocktail overnight, washed twice, and
then added to endothelial cell monolayers. After 24h incubation, the culture supernatants were analyzed for IL-6 by ELISA. Results are mean
± SEM of quadruplicate determinations of a representative experiment. Similar results were observed in two other experiments.
inhibitors did not potentiate the LPS-stimulated production
of IL-6. Interestingly, addition of 10μM diphenhydramine
to pretreated mast cells resulted in a small but signiﬁcant
(P<0.05) reduction in the eﬀect of MC + PI (Figure 4(c)).
In concordance with these ﬁndings we noted that addition
ofhumantryptase(50mU/mL)potentiatedtheLPS-induced
IL-6 production by HCAEC (Figure 5(c)).
3.6. Eﬀect of Histamine on BMP-2 Expression. Vascular calci-
ﬁcation is one of the complications of chronic inﬂammatory
diseases. BMP-2 is a powerful osteogenic morphogen which
belongs to TGF-β superfamily and plays a central role in
bone remodeling and calciﬁcation of atherosclerotic plaques
[32–36]. In order to determine whether histamine has a
role in the regulation of BMP-2, HCAEC monolayers were
treated with histamine (10μM) or LPS (100ng/mL) and the
expression of BMP-2 mRNA and protein were determined
using qRT-PCR and Western blot analysis, respectively. As
shown in Figure 6(a), incubation of HCAEC with histamine
resulted in 4-to 5-fold increase in BMP-2 mRNA expression
which was completely abrogated by cetirizine, an H1R
antagonist. Incubation of HCAEC with LPS also led to
increased expression of BMP-2 mRNA in a concentration-
dependent fashion (Figure 6(b)). Western blot analysis of
the total protein in cell lysates showed upregulation of
BMP-2 expression by histamine within 2h which sustained6 Mediators of Inﬂammation
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Figure 5: Histamine and Tryptase induce potentiation of IL-6 production by LPS-stimulated endothelial cells. Endothelial cells
(10,000cells/well) were incubated with histamine (10μM) (a and b) or human tryptase (50mU/mL) (c) in the presence or absence of
LPS (100ng/ml) for 24h. After the incubation, culture supernatants were analyzed for IL-6 by ELISA. To determine the eﬀect of H1R or
H2R antagonists, endothelial cells were incubated with 10 μM diphenhydramine (DPH) (a) or 10μM famotidine (FAM) (b) for 30min
before addition of histamine. Results are mean ± SEM of quadruplicate determinations of a representative experiment. Similar results were
observed in two other experiments.
up to 24h. In contrast, LPS-induced expression of BMP-2
proteinwastransient.Interestingly,thepresenceofhistamine
appears to block the decrease in BMP-2 protein noted with
LPS alone at 24h time point.
4. Discussion
The results obtained in this study demonstrate for the ﬁrst
time that coincubation of HCAEC and human mast cell
subclone HMC-1 5C6 leads to enhanced production of
IL-6 by both quiescent and LPS-stimulated HCAEC. The
enhanced levels of IL-6 were not derived from mast cells
because incubation of HMC-1 5C6 without HCAEC did not
produce IL-6 in the presence or absence of LPS (data not
shown). Furthermore, IL-6 was not detected in HMC-1 5C6
lysates conﬁrming that these cells did not contribute to the
observed increase in IL-6. Additional results revealed that
HMC-1 5C6-derived histamine and serine proteases mediate
IL-6 production directly as well as synergistically with LPS.
The present study also demonstrates that histamine induces
the expression of the osteogenic protein BMP-2 in HCAEC
suggesting an important role for mast cells in vascular
calciﬁcation.
Our laboratory has previously demonstrated synergistic
interaction between bacterial products and rat mast cell
granules on endothelial cells resulting in ampliﬁed pro-
duction of IL-6 and IL-8 [15–17]. In agreement with this
observation, human mast cell line HMC-1 5C6 at various
concentrationscorrespondingtomastcell-to-endothelialcell
ratios of 1:8, 1:4, 1:2, and 1:1 stimulated IL-6 production
by HCAEC (Figure 2). In addition, mast cells potentiated the
eﬀect of LPS at all the concentrations tested conﬁrming aMediators of Inﬂammation 7
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Figure 6: Histamine and LPS induce expression of BMP-2 mRNA. Endothelial cells were incubated with medium (control), histamine,
histamine + cetirizine (a), or with 10 or 100ng/mL LPS (b) for 2h. Total RNA was extracted, reverse transcribed and, analyzed using speciﬁc
primer sets for BMP-2 using real-time RT-PCR with β-actin as the housekeeping gene (a and b). Results were analyzed and normalized using
β-actin and expressed as fold changes over the control. (c) Endothelial cells were incubated with medium, histamine, LPS, or histamine +
LPS for 2 or 24h, and Western blotting was carried out to determine the expression of BMP-2 protein as described in details in the Section 2.
synergy between the mast cell and LPS. The ability of this
human mast cell line to act in concert with bacterial agent
to modulate endothelial cell function has important clinical
signiﬁcance.
Scanning electron microscopy revealed that HCAEC
and HMC-1 5C6 adhere to each other in the co-culture
(Figure 3). Since mast cell lysates also showed a similar eﬀect
on HCAEC (Table 1), we submit that an adherence between
intact mast cells and endothelial cells is not a prerequisite for
the mast cell-mediated endothelial activation. Whether this
cell-to-cell interaction involves selective adhesion molecules
or receptors on the endothelial cells is unknown. Previ-
ous transmission electron micrograph studies have shown
that mast cell-released granules (MCG) are internalized by
cultured human umbilical vein endothelial cells (HUVEC)
and remain morphologically intact for at least 24h [15].
This phenomenon of mast cell transgranulation has been
previously observed in human tissue [11]. The retention
of structurally intact MCG after being internalized by
endothelial cells is in contrast to the rapid degradation
observed in macrophages [37]. The strategic location of
mast cells in the vessel wall and their demonstrated abil-
ity to modulate endothelial cell functions emphasize the
importance of an active communication between these two
cell types. Transmission electron microscopy of the HMC-1
5C6 clone exhibited electron-dense particles in the granule
compartments (Figure 3). These electron-dense particles
were not detected in the parent HMC-1 cell line [38]. Thus,
the HMC-1 5C6 clone appears to be functionally mature and
suitable for evaluating mast cell functions.
Among the secreted products of the mast cell, histamine
and proteases are the most extensively studied molecules.
On a weight and molar basis, neutral proteases are the
major exocytosed protein constituents of activated mast cells
[20]. Tryptase, chymase, and carboxypeptidase A, represent
the three major classes of proteases stored in the granules
of mast cells [20–23]. Present results show that mast cell-
induced activation of HCAEC was partly due to serine
proteases. Pretreatment of mast cells with a cocktail of
protease inhibitors (PI) partially abrogated the stimulation
of IL-6 production by quiescent and LPS-activated HCAEC
(Figure 4(c)) suggesting that proteases released by mast
cells participate in endothelial activation. Human mast cell
tryptase has been shown to induce or potentiate IL-8 and
ICAM-1 expression in bronchial epithelial cells [39], IL-8
production in endothelial cells [40], collagen synthesis and
chemotaxis in ﬁbroblasts [41], and to initiate angiogenesis
[42]. Mast cell chymase and carboxypeptidase A degrade
low-density lipoprotein [13, 14]. The mouse mast cell
protease-6, which is homologous to human β-tryptase,8 Mediators of Inﬂammation
induces inﬁltration of neutrophils in vivo andstimulates IL-8
production by endothelial cells [43]. Evidence also indicates
thepresenceofincreasedmastcellnumbersandextracellular
tryptase within the atherosclerotic plaques during early
stages of calciﬁcation [10]. Results presented in Figure 5(c)
demonstrate that incubation of HCAEC with tryptase results
in signiﬁcant increase in the production of IL-6 by HCAEC,
which was further enhanced by the presence of LPS in the
cell culture. These results suggest that tryptase and LPS
can act in concert to amplify inﬂammatory response in the
endothelium.
Histamine is well recognized for its role in the regulation
of vasodilatation [44, 45] and endothelial cell functions [26].
Adirectrelationshipbetweenhistamineandvascularinﬂam-
mation is evident from the increased levels of histamine in
the coronary arteries of patients with ischemic heart disease
[2] and by the elevated levels of histamine in the coronary
circulation of patients with variant angina [24]. The ability
of mast cell-derived histamine to induce IL-6 production
by HCAEC suggests that it is an important inﬂammatory
mediator in the coronary vasculature.The inﬂammatory and
hypersensitivity responses elicited by histamine are mediated
through a family of four distinct G-protein-coupled recep-
t o r s ,H 1 R ,H 2 R ,H 3 R ,a n dH 4 R[ 46–49]. The H1 receptor
subtype is highly expressed in endothelial cells and smooth
muscle cells. In the present study, IL-6 production induced
by mast cells or by their synergistic action with LPS was
partially inhibited by the H1R antagonist, diphenhydramine,
but not by the H2R antagonist, famotidine (Figures 4(a)
and 4(b)). Furthermore, the direct and synergistic eﬀect of
exogenous histamine on IL-6 production was signiﬁcantly
abrogated by the H1R antagonist (Figure 5(a))b u tn o t
by H2R antagonist (Figure 5(b)). However, a complete
abrogationofthestimulatoryeﬀectofintactmastcellsonIL-
6 production was noted only when both the protease activity
and the H1R function were blocked (Figure 4(c)).
Although recognized as an early phase reactant, the role
of histamine in the delayed eﬀects of inﬂammation on the
vasculatureisnotclear.Asdiscussedabove,thedirectcellular
eﬀect of histamine and its ability to synergize LPS-induced
IL-6 production underscores its role in amplifying the
inﬂammatoryresponsesassociatedwithinfection.Prolonged
interaction of histamine and LPS with endothelial cells
results in vascular dysfunction. Other pro-inﬂammatory
molecules such as C-reactive protein [32], oxysterols and
TNF-α play a role in calciﬁcation via calcifying vascular cells,
a type of vascular smooth muscle cells [33–35]. Calciﬁcation
involves mechanisms similar to osteogenic mineralization
[29] and the bone morphogen BMP-2 is expressed in
calcifying atherosclerotic plaques [28]. BMP-2 is a powerful
osteogenic morphogen which belongs to the transforming
growth factor-beta (TGF-β) superfamily. Activated endothe-
lial cells are known to release osteo/chondrocytic molecules
such as BMPs [50, 51]. BMP-2 is a key participant in calciﬁed
atherosclerotic plaques [36], and its expression is enhanced
by TNF-α or mechanical stimuli [52]. We have shown that
mice deﬁcient in mast cells and histamine are osteoporotic
and osteoclast deﬁcient, and they exhibit bone abnormalities
[53] indicating a role for mast cells in the regulation of bone
formation and calciﬁcation. Furthermore, a recent study
demonstrated communication between BMP-2 and mast
cells during heterotopic ossiﬁcation [54]. Our present study
demonstrating increased expression of BMP-2 mRNA and
protein in histamine-treated HCAEC supports the idea that
mast cell-derived histamine may modulate early events in
vascular calciﬁcation. In this context, it is noteworthy that
histamine has been shown to cause soft tissue calciﬁcation
[55]. To our knowledge, this is the ﬁrst study which links the
roleofhistamineintheregulationofBMP-2andmayexplain
the bone abnormalities in mast cell deﬁciency.
5. Conclusions
The present study demonstrates that human mast cell line
HMC-1 5C6 is capable of inducing the production of IL-
6 by interacting with quiescent and LPS-induced HCAEC.
The stimulatory eﬀect of HMC-1 5C6 on LPS-mediated
activation was synergistic in nature and was mediated by
histamine and proteases. Exogenously added histamine and
tryptase mimicked the direct and potentiating eﬀects of LPS
on IL-6 production. Another novel ﬁnding of this study
is that histamine is capable of inducing the expression
of the osteogenic protein BMP-2. Collectively, our results
suggest that mast cell-derived histamine and proteases play
an important role in vascular inﬂammation and calciﬁcation
in addition to their well-recognized participation in allergic
diseases.
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